Overcoming barriers to biosimilars in inflammatory arthritis
暂无分享，去创建一个
[1] K. Petrie,et al. Effects of Message Framing on Patients’ Perceptions and Willingness to Change to a Biosimilar in a Hypothetical Drug Switch , 2020, Arthritis care & research.
[2] Inge Christoffer Olsen,et al. Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial , 2019, Journal of internal medicine.
[3] A. Loft,et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry , 2018, Annals of the rheumatic diseases.
[4] S. Teerenstra,et al. Open‐Label, Non‐Mandatory Transitioning From Originator Etanercept to Biosimilar SB4 , 2018, Arthritis & rheumatology.
[5] Inge Christoffer Olsen,et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial , 2017, The Lancet.
[6] T. Dörner,et al. Biosimilars in rheumatology: current perspectives and lessons learnt , 2015, Nature Reviews Rheumatology.